Tue, 26 Jan 2021

Mumbai (Maharashtra) [India], November 29 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd. today announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories Ltd. to divest - subject to completion of certain precedent actions and closing activities - its brand Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along with rights to the trademarks, dossiers and patents for the territories mentioned.

The divested brand and its extensions represent two types of products, (a) Mometasone mono product and (b) combination of Mometasone with Azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.

"In line with our strategy to launch Ryaltris, our global anti-allergy brand, in the markets of Russia and other CIS countries, we decided to divest the Momat Rino brand and its extension. As we await approval to launch Ryaltris in the Russian market, we look forward to strengthening our respiratory franchise in the Russia/CIS region. We remain committed to the respiratory space globally," said Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals Limited.

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

More Central Asia News

Access More

Sign up for Mongolia News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!